Modality
Gene Editing
MOA
Anti-Tau
Target
Aβ
Pathway
Ferroptosis
Cervical Ca
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
Aug 2022
→ Mar 2029
Phase 1Current
NCT08377886
2,261 pts·Cervical Ca
2022-08→2027-05·Not yet recruiting
NCT08053256
1,534 pts·Cervical Ca
2023-09→2029-03·Active
3,795 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-10-016mo agoPDUFA· Cervical Ca
2027-05-031.1y awayPh2 Data· Cervical Ca
2029-03-012.9y awayPh2 Data· Cervical Ca
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Not yet…
P1/2
Active
Catalysts
PDUFA
2025-10-01 · 6mo ago
Cervical Ca
Ph2 Data
2027-05-03 · 1.1y away
Cervical Ca
Ph2 Data
2029-03-01 · 2.9y away
Cervical Ca
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08377886 | Phase 1/2 | Cervical Ca | Not yet recr... | 2261 | 6MWD |
| NCT08053256 | Phase 1/2 | Cervical Ca | Active | 1534 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |